Alnylam Pharma (ALNY) Misses Q3 EPS by 42c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity
November 7, 2018 8:00 AM ESTObtained FDA and EMA Approvals of ONPATTRO (patisiran) the First-Ever RNAi Therapeutic and Launched in U.S. and EU
Received 125 U.S. Patient Start Forms in First Seven Weeks of ONPATTRO Launch
Reported Positive Topline Interim Analysis Results from ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyrias
Advanced Lumasiran into ILLUMINATE Phase 3 Program
Maintained Strong Balance Sheet with $1.27 Billion in Cash and Expects to End 2018 with Approximately $1.0 Billion in Cash
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
